Thymosin α1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1

Biochemical and Biophysical Research Communications

Volumn 464, Issue 1, 2015, Pages 249-255

  Yuan, Chao ^a,b   Zheng, Yisheng ^c   Zhang, Bo ^a,b   Shao, Lijuan ^a   Liu, Yang ^a   Tian, Tian ^a   Gu, Xiaobin ^a   Li, Xiangnan ^d   Fan, Kexing ^a,b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Arginase 1; Lung cancer; MyD88; Myeloid derived suppressor cells; Thymosin 1

Indexed keywords

ARGINASE 1; CYCLOOXYGENASE 2; GEMCITABINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; N(G) METHYLARGININE; PROGRAMMED DEATH 1 LIGAND 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; ARG1 PROTEIN, MOUSE; ARGINASE; MYD88 PROTEIN, MOUSE; THYMOSIN; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER THERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARCINOMA, LEWIS LUNG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; MORTALITY; PATHOLOGY; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ARGINASE; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNITY, INNATE; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; THYMOSIN; TOLL-LIKE RECEPTORS;

EID: 84937634687     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.06.132     Document Type: Article

References (33)

1. A.L. Goldstein, A. Guha, M.M. Zatz, and M.A. Hardy Purification and biological activity of thymosin, a hormone of the thymus gland Proc. Natl. Acad. Sci. U. S. A. 69 1972 1800 1803
2. C. Giuliani, G. Napolitano, A. Mastino, S. Di Vincenzo, C. D'Agostini, S. Grelli, I. Bucci, D.S. Singer, L.D. Kohn, and F. Monaco Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level Eur. J. Immunol. 30 2000 778 786
3. A. Ahmed, D.M. Wong, G.B. Thurman, T.L. Low, A.L. Goldstein, S.J. Sharkis, and I. Goldschneider T-lymphocyte maturation: cell surface markers and immune function induced by T-lymphocyte cell-free products and thymosin polypeptides Ann. N. Y. Acad. Sci. 332 1979 81 94
4. C. Favalli, T. Jezzi, A. Mastino, C. Rinaldi-Garaci, C. Riccardi, and E. Garaci Modulation of natural killer activity by thymosin alpha 1 and interferon Cancer Immunol. Immunother. 20 1985 189 192
5. L. Romani, F. Bistoni, R. Gaziano, K. Perruccio, L. Pitzurra, S. Bellocchio, A. Velardi, G. Rasi, P. Di Francesco, and E. Garaci Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling Blood 103 2004 4232 4239
6. A.L. Goldstein, and A.L. Goldstein From lab to bedside: emerging clinical applications of thymosin alpha 1 Expert Opin. Biol. Ther. 9 2009 593 608
7. M. Maio, A. Mackiewicz, A. Testori, U. Trefzer, V. Ferraresi, J. Jassem, C. Garbe, T. Lesimple, B. Guillot, P. Gascon, F. Cognetti, and G. Thymosin Melanoma investigation, large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma J. Clin. Oncol. 28 2010 1780 1787
8. R.G. Gish, S.C. Gordon, D. Nelson, V. Rustgi, and I. Rios A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma Hepatol. Int. 3 2009 480 489
9. A. Sungarian, D. Cielo, P. Sampath, N. Bowling, P. Moskal, J.R. Wands, and S.M. de la Monte Potential role of thymosin-alpha1 adjuvant therapy for glioblastoma J. Oncol. 2009 2009 302084
10. T.W. Moody, C. Tuthill, M. Badamchian, and A.L. Goldstein Thymosin alpha1 inhibits mammary carcinogenesis in fisher rats Peptides 23 2002 1011 1014
11. E. Garaci, F. Pica, A. Serafino, E. Balestrieri, C. Matteucci, G. Moroni, R. Sorrentino, M. Zonfrillo, P. Pierimarchi, and P. Sinibaldi-Vallebona Thymosin alpha1 and cancer: action on immune effector and tumor target cells Ann. N. Y. Acad. Sci. 1269 2012 26 33
12. X. Lao, M. Liu, J. Chen, and H. Zheng A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1 PLoS One 8 2013 e72242
13. S. Ostrand-Rosenberg, and P. Sinha Myeloid-derived suppressor cells: linking inflammation and cancer J. Immunol. 182 2009 4499 4506
14. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 9 2009 162 174
15. J.I. Youn, S. Nagaraj, M. Collazo, and D.I. Gabrilovich Subsets of myeloid-derived suppressor cells in tumor-bearing mice J. Immunol. 181 2008 5791 5802
16. M.K. Srivastava, L. Zhu, M. Harris-White, M.F. Johnson, J.M. Lee, D. Elashoff, R. Strieter, S. Dubinett, and S. Sharma Myeloid suppressor cell depletion augments antitumor activity in lung cancer PLoS One 7 2012 e40677
17. R.F. Gabitass, N.E. Annels, D.D. Stocken, H.A. Pandha, and G.W. Middleton Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 Cancer Immunol. Immunother. 60 2011 1419 1430
18. B. Weide, A. Martens, H. Zelba, C. Stutz, E. Derhovanessian, A.M. Di Giacomo, M. Maio, D. Schadendorf, P. Buttner, C. Garbe, and G. Pawelec Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells Clin. Cancer Res. 20 2014 1601 1609
19. S. Solito, E. Falisi, C.M. Diaz-Montero, A. Doni, L. Pinton, A. Rosato, S. Francescato, G. Basso, P. Zanovello, A.J. Montero, V. Bronte, and S. Mandruzzato A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells Blood 118 2011 2254 2265
20. A. Huang, B. Zhang, B. Wang, F. Zhang, K.X. Fan, and Y.J. Guo Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients Cancer Immunol. Immunother. 62 2013 1439 1451
21. C.H. Serezani, J.H. Perrela, M. Russo, M. Peters-Golden, and S. Jancar Leukotrienes are essential for the control of Leishmania amazonensis infection and contribute to strain variation in susceptibility J. Immunol. 177 2006 3201 3208
22. D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G.J. Adema The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells Immunology 138 2013 105 115
23. E. Suzuki, V. Kapoor, A.S. Jassar, L.R. Kaiser, and S.M. Albelda Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin. Cancer Res. 11 2005 6713 6721
24. Y. Liu, X. Xiang, X. Zhuang, S. Zhang, C. Liu, Z. Cheng, S. Michalek, W. Grizzle, and H.G. Zhang Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells Am. J. Pathol. 176 2010 2490 2499
25. M.J. Delano, P.O. Scumpia, J.S. Weinstein, D. Coco, S. Nagaraj, K.M. Kelly-Scumpia, K.A. O'Malley, J.L. Wynn, S. Antonenko, W.H. Reeves, A. Ayala, D. Laface, P.G. Heyworth, M. Clare-Salzler, and L.L. Moldawer MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis J. Exp. Med. 204 2007 1463 1474
26. M. Compagno, W.K. Lim, A. Grunn, S.V. Nandula, M. Brahmachary, Q. Shen, F. Bertoni, M. Ponzoni, M. Scandurra, A. Califano, G. Bhagat, A. Chadburn, R. Dalla-Favera, and L. Pasqualucci Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 459 2009 717 721
27. C. Ni, P. Wu, X. Wu, T. Zhang, T. Zhang, Z. Wang, S. Zhang, F. Qiu, and J. Huang Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression Cancer Lett. 356 2015 579 588
28. X. Peng, P. Zhang, X. Wang, J. Chan, C. Tuthill, Y. Wan, A.M. Dragoi, and W.M. Chu Signaling pathways leading to the activation of IKK and MAPK by thymosin alpha1 Ann. N. Y. Acad. Sci. 1112 2007 339 350
29. L. Romani, F. Bistoni, K. Perruccio, C. Montagnoli, R. Gaziano, S. Bozza, P. Bonifazi, G. Bistoni, E. Garaci, and P. Puccetti Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance Blood 108 2006 2265 2274
30. L.A. Ridnour, R.Y. Cheng, C.H. Switzer, J.L. Heinecke, S. Ambs, S. Glynn, H.A. Young, G. Trinchieri, and D.A. Wink Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity Clin. Cancer Res. 19 2013 1340 1346
31. K.H. Yoo, T.J. Lim, and S.G. Chang Monthly intravesical bacillus Calmette-Guerin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute Exp. Ther. Med. 3 2012 221 225
32. A.M. Krieg Toll-like receptor 9 (TLR9) agonists in the treatment of cancer Oncogene 27 2008 161 167
33. A. Maruyama, H. Shime, Y. Takeda, M. Azuma, M. Matsumoto, and T. Seya Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling Biochem. Biophys. Res. Commun. 457 2015 445 450